ABI
RVNC

Adamant Biomedical Investments’s Revance Therapeutics, Inc. RVNC Stock Holding History

Adamant Biomedical Investments’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-130,000
Closed -$2.51M – 105
2014
Q3 		$2.51M Buy
+130,000
New +$3.39M 0.63% 53

Other funds holding RVNC

EWM
Essex Woodlands Management The Woodlands, Texas $254M AUM 4.59% 1-Year Est. Return
NHG
NQ HCIF GP Raleigh, North Carolina $50.2M AUM 45.53% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

Adamant Biomedical Investments's RVNC Position: Q4 2014 in Review

Adamant Biomedical Investments sold out of Revance Therapeutics, Inc. (RVNC) in Q4 2014, closing a stake of 130,000 shares — an estimated $2.51M sold.

Adamant Biomedical Investments first reported a position in RVNC in Q3 2014 and held it in 1 quarter. The position peaked at $2.51M in Q3 2014. 69 funds tracked by Wall St. Rank hold RVNC as of Q4 2014.

  • Adamant Biomedical Investments reported no remaining Revance Therapeutics, Inc. position as of Q4 2014 after selling out during the quarter.
  • Adamant Biomedical Investments sold 130,000 Revance Therapeutics, Inc. shares in Q4 2014, an estimated $2.51M.
  • Adamant Biomedical Investments first reported a position in Revance Therapeutics, Inc. in Q3 2014 and held it in 1 quarter.
  • Adamant Biomedical Investments's Revance Therapeutics, Inc. position peaked at $2.51M in Q3 2014.
  • 69 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q4 2014.

Based on Adamant Biomedical Investments's 13F filing for Q4 2014, filed 13 Feb 2015.